News Releases

Below are the latest News Releases for Clearmind Medicine Inc.

16

June

2023

Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
Read More
22

May

2023

Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Dis
Read More
17

May

2023

Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
Read More
12

May

2023

Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder
Read More
8

May

2023

Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam
Read More
2

May

2023

Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial
Read More
27

April

2023

Clearmind Medicine Forms a Data and Safety Monitoring Board to Oversee its First-in-Human Clinical Trial
Read More
21

April

2023

Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
Read More
20

April

2023

Clearmind Medicine Engages Experienced Contract Research Organization to Support its First-in-Human Clinical Trial
Read More
6

April

2023

Clearmind Medicine Closes US$3.5 Million Public Offering
Read More
16

March

2023

Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder
Read More
14

March

2023

Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D. to Scientific Advisory Board
Read More
22

February

2023

Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds
Read More
15

February

2023

Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
Read More
8

February

2023

Israel-Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
Read More